DGAP-Adhoc: Eckert & Ziegler Increases Profit Forecast to 4 Euro per Share
DGAP-Ad-hoc: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Forecast/Change in Forecast Insider information pursuant to Article 17 MAR The consolidated result in the first half of the year should reach EUR 2.47 per share (Q2 previous year: EUR 2.59). At the same time sales should run to about EUR 84 million (Q2 previous year: EUR 89 million). On the basis of this evaluation, and despite Corona, the Executive Board expects the consolidated result for the financial year 2020 to exceed the forecast published at the beginning of the year. It therefore rescinds the previous guidance and increases the target of EUR 3.50 to EUR 4.00 per share. The Executive Board keeps the revenue forecast at EUR 170 million. The figures are based on the share capital as of 30 June 2020. Converted to the increased share capital of EUR 21,171,932, the forecast is EUR 1.00 per share. Your contact:
24-Jul-2020 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
Language: | English |
Company: | Eckert & Ziegler Strahlen- und Medizintechnik AG |
Robert-Rössle-Str.10 | |
13125 Berlin | |
Germany | |
Phone: | +49 30 941084-138 |
Fax: | +49 30 941084-112 |
E-mail: | [email protected] |
Internet: | www.ezag.de |
ISIN: | DE0005659700 |
WKN: | 565970 |
Indices: | SDAX |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
EQS News ID: | 1100997 |
End of Announcement | DGAP News Service |
|
1100997 24-Jul-2020 CET/CEST
Eckert & Ziegler Strahlen- und Medizintechnik AG Aktie
Positive Tendenz für Eckert & Ziegler Strahlen- und Medizintechnik AG mit mehreren Buy- und keiner Sell-Einschätzung.
Das durchschnittliche Community-Kursziel von 95 € für Eckert & Ziegler Strahlen- und Medizintechnik AG deutet auf eine Verdopplung des aktuellen Kurses von 45.78 € hin.